OPTIMAL: A Multinational Phase III Study of Oral Paclitaxel (DHP107) versus Intravenous Weekly Paclitaxel in HER2-Negative Recurrent or Metastatic Breast Cancer

20260 citationsJournal Articlehybrid Open Access

Authors

B. Xu · Chinese Academy of Medical Sciences & Peking Union Medical College

H. Jeong · Ulsan College

T. Sun · Liaoning Cancer Hospital & Institute

J. Sohn · Yonsei University

Q. Zhang · Harbin Medical University

S. Kostic · University Hospital Medical Center Bezanijska kosa

X. Wang

Abstract

DHP107 demonstrated non-inferior efficacy compared to IV paclitaxel, with a manageable safety profile, supporting its use as an effective and convenient alternative in HER2-negative breast cancer.

Topics & Keywords

Cancer Treatment and Pharmacology HER2/EGFR in Cancer Research Advanced Breast Cancer Therapies

Publication Details

Published in: Annals of Oncology

DOI: 10.1016/j.annonc.2026.03.002

Field-Weighted Citation Impact: 0.00

Command Palette

OPTIMAL: A Multinational Phase III Study of Oral Paclitaxel (DHP107) versus Intravenous Weekly Paclitaxel in HER2-Negative Recurrent or Metastatic Breast Cancer

Authors

Abstract

Topics & Keywords

Publication Details